No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
36-482-hyaluronoglucosaminidase ph20 (rhuph20) |
Hyaluronidase |
D04455, D04456, D06604 |
- |
- |
[1] 65 |
2 |
Abatacept |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
3 |
Ada gene transfer |
- |
- |
- |
- |
[1] 65 |
4 |
Ada pbsc |
- |
- |
- |
- |
[1] 65 |
5 |
Ada umbilical cord blood cells |
- |
- |
- |
- |
[1] 65 |
6 |
Adagen |
Pegademase |
D05384 |
- |
- |
[1] 65 |
7 |
Adenosine |
Adenosine |
D00045 |
[4] ADORA1, ADORA2A, ADORA2B, ADORA3 |
[12] Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[3] 13, 58, 65 |
8 |
Administration of drug (interferon-gamma 1-b) subcutaneously |
- |
- |
- |
- |
[1] 65 |
9 |
Adverse reactions of gammagard subcutaneously at week 12 |
- |
- |
- |
- |
[1] 65 |
10 |
Adverse reactions of gammagard subcutaneously at week 24 |
- |
- |
- |
- |
[1] 65 |
11 |
Adverse reactions of gammagard subcutaneously at week 36 |
- |
- |
- |
- |
[1] 65 |
12 |
Adverse reactions of gammagard subdermally at week 12 |
- |
- |
- |
- |
[1] 65 |
13 |
Adverse reactions of gammagard subdermally at week 24 |
- |
- |
- |
- |
[1] 65 |
14 |
Adverse reactions of gammagard subdermally at week 36 |
- |
- |
- |
- |
[1] 65 |
15 |
Aldesleukin |
Aldesleukin |
D00748 |
[3] IL2RA, IL2RB, IL2RG |
[14] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
[3] 49, 65, 97 |
16 |
Alefacept |
Alefacept |
D02800 |
[1] CD58 |
[2] Cell adhesion molecules (CAMs), Epstein-Barr virus infection |
[6] 37, 60, 65, 164, 284, 285 |
17 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
[13] 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
18 |
Alemtuzumab 0.2 mg |
Alemtuzumab |
D02802 |
- |
- |
[2] 65, 164 |
19 |
Alemtuzumab 0.3 mg |
Alemtuzumab |
D02802 |
- |
- |
[2] 65, 164 |
20 |
Allogeneic peripheral blood stem cell |
- |
- |
- |
- |
[1] 65 |
21 |
Amlodipine |
Amlodipine |
D00615, D02914, D07450 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[4] 51, 65, 67, 298 |
22 |
Anti-cd45 |
- |
- |
- |
- |
[3] 60, 65, 285 |
23 |
Anti-thymocyte globulin |
- |
- |
- |
- |
[18] 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
24 |
Anti-thymocyte globulin (rabbit) |
Rabbit |
- |
- |
- |
[3] 60, 65, 285 |
25 |
Antithymocyte globulin |
- |
- |
- |
- |
[3] 60, 65, 284 |
26 |
Antithymocyte immunoglobulin (rabbit) |
Rabbit |
- |
- |
- |
[2] 13, 65 |
27 |
Aproart |
- |
- |
- |
- |
[1] 65 |
28 |
Asp1517 |
- |
- |
- |
- |
[1] 65 |
29 |
Autologous cd34+ cell transduced with g2scid vector |
- |
- |
- |
- |
[1] 65 |
30 |
Autologous cd34+ cells transduced ex-vivo with the pcclchimgp91/vsvg lentiviral vector |
- |
- |
- |
- |
[1] 65 |
31 |
Autologous cd34+ cells transduced with a lentiviral vector encoding the wasp cdna |
- |
- |
- |
- |
[1] 65 |
32 |
Autologous cd34+ cells transduced with the lentiviral vector containing the human wiskott aldrich sy |
- |
- |
- |
- |
[1] 65 |
33 |
Autologous cd34+cells transduced with the w1.6_hwasp_wpre (vsvg) lentiviral vector |
- |
- |
- |
- |
[1] 65 |
34 |
Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv) |
Adenosine |
D00045 |
[4] ADORA1, ADORA2A, ADORA2B, ADORA3 |
[12] Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 65 |
35 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
[18] 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
36 |
Azelnidipine |
Azelnidipine |
D01145 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 65 |
37 |
B-lymphocyte stimulator (blys) |
- |
- |
- |
- |
[1] 65 |
38 |
Bacteriophage |
- |
- |
- |
- |
[1] 65 |
39 |
Basiliximab |
Basiliximab |
D03058 |
[1] IL2RA |
[11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[6] 2, 50, 65, 97, 222, 228 |
40 |
Benznidazole |
Benznidazole |
D02489 |
- |
- |
[1] 65 |
41 |
Betamethasone |
Betamethasone |
D00244, D00972, D01357, D01402, D01637, D02032, D02286 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[6] 2, 46, 65, 90, 96, 235 |
42 |
Biological sampling |
- |
- |
- |
- |
[1] 65 |
43 |
Bivigam |
Immune globulin human |
- |
- |
- |
[1] 65 |
44 |
Bms-188667 |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[6] 46, 49, 65, 96, 97, 271 |
45 |
Bpx-501 t cells |
- |
- |
- |
- |
[4] 65, 284, 285, 326 |
46 |
Bt090 |
- |
- |
- |
- |
[1] 65 |
47 |
Bt524 |
- |
- |
- |
- |
[1] 65 |
48 |
Bt595 |
- |
- |
- |
- |
[2] 63, 65 |
49 |
Bt681 |
- |
- |
- |
- |
[1] 65 |
50 |
Busilvex |
- |
- |
- |
- |
[4] 19, 36, 60, 65 |
51 |
Busulfan |
Busulfan |
D00248 |
- |
- |
[13] 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 |
52 |
Busulfan iv |
Busulfan |
D00248 |
- |
- |
[1] 65 |
53 |
Busulfan, cyclophosphamide, atg, gcsf |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[2] 65, 284 |
54 |
Busulfan, fludarabine and atg |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[1] 65 |
55 |
Busulfan, fludarabine, atg, tli |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[2] 65, 284 |
56 |
C1 inhibitor |
Human c1-esterase inhibitor |
- |
- |
- |
[1] 65 |
57 |
C1 inhibitor concentrate |
Human c1-esterase inhibitor |
- |
- |
- |
[1] 65 |
58 |
C1-esterase inhibitor [recombinant] (c1-inh-r) |
Human c1-esterase inhibitor |
- |
- |
- |
[1] 65 |
59 |
C1-inh |
Human c1-esterase inhibitor |
- |
- |
- |
[1] 65 |
60 |
Calcium |
Calcium |
- |
- |
- |
[24] 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
61 |
Calcium channel blockers (amlodipine, azelnidipine) |
Azelnidipine |
D01145 |
[4] CACNA1C, CACNA1D, CACNA1F, CACNA1S |
[34] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 65 |
62 |
Campath |
Alemtuzumab |
D02802 |
- |
- |
[4] 49, 51, 60, 65 |
63 |
Campath -1h |
- |
- |
- |
- |
[1] 65 |
64 |
Campath 1h |
Alemtuzumab |
D02802 |
- |
- |
[4] 60, 65, 164, 285 |
65 |
Campath, fludarabine, cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[2] 65, 284 |
66 |
Cd3/cd19 neg allogeneic bmt |
- |
- |
- |
- |
[1] 65 |
67 |
Cd3/cd19 negative allogeneic hematopoietic stem cells |
- |
- |
- |
- |
[1] 65 |
68 |
Cd34 stem cell selection therapy |
- |
- |
- |
- |
[3] 60, 65, 284 |
69 |
Cd34+ |
- |
- |
- |
- |
[1] 65 |
70 |
Cd34+ cells transduced with ada retrovir |
- |
- |
- |
- |
[1] 65 |
71 |
Cd34+ hscs transduced with the lentivirus vector, vsv-g pseudotyped cl20-4i-ef1a-h?c-opt |
- |
- |
- |
- |
[1] 65 |
72 |
Cd34+cells |
- |
- |
- |
- |
[2] 65, 285 |
73 |
Choline |
Choline |
D07690 |
- |
- |
[4] 65, 171, 193, 299 |
74 |
Cutaquig |
Immune globulin human |
- |
- |
- |
[1] 65 |
75 |
Cuvitru |
Immune globulin human |
- |
- |
- |
[1] 65 |
76 |
Cuvitru 200 mg/ml solution for subcutaneous injection |
Immune globulin human |
- |
- |
- |
[1] 65 |
77 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[43] 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
78 |
Cyclophosphamide 30 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[3] 65, 285, 326 |
79 |
Cyclophosphamide 40 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[3] 65, 285, 326 |
80 |
Cyclophosphamide dose level 1 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[2] 65, 284 |
81 |
Cyclophosphamide dose level 2 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[2] 65, 284 |
82 |
Cyclophosphamide dose level 3 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[2] 65, 284 |
83 |
Cyclophosphamide dose level 4 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[2] 65, 284 |
84 |
Cyclophosphamide post transplant |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[1] 65 |
85 |
Cyclosporine |
Ciclosporin |
D00184 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[33] 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
86 |
Cyclosporins |
- |
- |
- |
- |
[4] 53, 60, 65, 222 |
87 |
Daclizumab |
Daclizumab |
D03639 |
[1] IL2RA |
[11] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
[7] 13, 56, 60, 65, 97, 283, 284 |
88 |
Danazol |
Danazol |
D00289 |
[3] AR, ESR1, PGR |
[11] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
[4] 60, 64, 65, 285 |
89 |
Db289 |
- |
- |
- |
- |
[1] 65 |
90 |
Depletion in cd45ra graft donor |
- |
- |
- |
- |
[1] 65 |
91 |
Dexamethasone |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[20] 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
92 |
Dexamethasone sodium phosphate |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[2] 65, 96 |
93 |
Dexamethasone sodium phosphate ph. eur. |
Dexamethasone |
D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 65 |
94 |
Dextrose, 5% in water |
Water |
D00001 |
- |
- |
[1] 65 |
95 |
Donor peripheral blood stem cells. |
- |
- |
- |
- |
[1] 65 |
96 |
Durvalumab |
Durvalumab |
D10808 |
[1] CD274 |
[2] Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer |
[1] 65 |
97 |
Efficacy of gammagard subcutaneously at week 12 |
- |
- |
- |
- |
[1] 65 |
98 |
Efficacy of gammagard subcutaneously at week 24 |
- |
- |
- |
- |
[1] 65 |
99 |
Efficacy of gammagard subcutaneously at week 36 |
- |
- |
- |
- |
[1] 65 |
100 |
Efficacy of gammagard subdermally at week 12 |
- |
- |
- |
- |
[1] 65 |
101 |
Efficacy of gammagard subdermally at week 24 |
- |
- |
- |
- |
[1] 65 |
102 |
Efficacy of gammagard subdermally at week 36 |
- |
- |
- |
- |
[1] 65 |
103 |
Eflornithine |
Eflornithine |
D07883 |
[1] ODC1 |
[3] Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
[1] 65 |
104 |
Eflornithine plus nifurtimox combination therapy |
Eflornithine |
D07883 |
[1] ODC1 |
[3] Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
[1] 65 |
105 |
Elapegademase |
Elapegademase |
D11017 |
[1] ADA |
[3] Metabolic pathways, Primary immunodeficiency, Purine metabolism |
[1] 65 |
106 |
Elapegademase-lvlr |
Elapegademase |
D11017 |
[1] ADA |
[3] Metabolic pathways, Primary immunodeficiency, Purine metabolism |
[1] 65 |
107 |
Ep2006 |
- |
- |
- |
- |
[1] 65 |
108 |
Ep2006 (filgrastim) |
Filgrastim |
D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[1] 65 |
109 |
Etoposide |
Etoposide |
D00125, D04107 |
[2] TOP2A, TOP2B |
[1] Platinum drug resistance |
[11] 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
110 |
Ezn-2279 |
- |
- |
- |
- |
[1] 65 |
111 |
Fansidar (pyrimethamine and sulfadoxine) |
Pyrimethamine |
D00488 |
- |
- |
[1] 65 |
112 |
Fexinidazole |
Fexinidazole |
D11252 |
- |
- |
[1] 65 |
113 |
Fg-4592/asp1517 - 100 mg |
- |
- |
- |
- |
[1] 65 |
114 |
Fg-4592/asp1517 - 20 mg |
- |
- |
- |
- |
[1] 65 |
115 |
Fg-4592/asp1517 - 50 mg |
- |
- |
- |
- |
[1] 65 |
116 |
Fibrinogen |
Fibrinogen human |
- |
- |
- |
[3] 14, 65, 288 |
117 |
Fibrinogen concentrate from human plasma |
Fibrinogen human |
- |
- |
- |
[1] 65 |
118 |
Filgrastim |
Filgrastim |
D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[25] 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
119 |
Filgrastim hexal |
Filgrastim |
D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[1] 65 |
120 |
Filgrastim, alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
[1] 65 |
121 |
Flebogamma 5% dif |
- |
- |
- |
- |
[1] 65 |
122 |
Fludarabina |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[1] 65 |
123 |
Fludarabina teva |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[1] 65 |
124 |
Fludarabine |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[17] 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
125 |
Fludarabine monophosphate |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[4] 49, 65, 284, 326 |
126 |
Fludarabine phosphate |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[11] 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285 |
127 |
Fludarabine phosphate 30 mg |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[2] 65, 164 |
128 |
Fludarabine phosphate 40 mg |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[2] 65, 164 |
129 |
Fludarabine, busulfan, thymoglobulin |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[1] 65 |
130 |
Fludarabine, melphalan, thiotepa |
Fludarabine |
D01907, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[1] 65 |
131 |
Fucose |
Fucose |
- |
- |
- |
[1] 65 |
132 |
G-csf |
Filgrastim |
D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[12] 6, 13, 16, 49, 51, 60, 65, 85, 96, 284, 285, 331 |
133 |
G-csf for conditioning before hsct. |
Filgrastim |
D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[1] 65 |
134 |
G1xcg |
- |
- |
- |
- |
[1] 65 |
135 |
G1xcgd transduced cd34+ cells |
- |
- |
- |
- |
[1] 65 |
136 |
Gadolinium |
Gadolinium |
- |
- |
- |
[6] 13, 34, 46, 58, 65, 305 |
137 |
Gadolinium for abdomen |
Gadolinium |
- |
- |
- |
[1] 65 |
138 |
Gadolinium for lower back |
Gadolinium |
- |
- |
- |
[1] 65 |
139 |
Gammagard liquid |
Immune globulin human |
- |
- |
- |
[1] 65 |
140 |
Gammagard s/d (solvent/detergent) |
Immune globulin human |
- |
- |
- |
[1] 65 |
141 |
Gammaglobulin |
- |
- |
- |
- |
[1] 65 |
142 |
Gammanorm |
- |
- |
- |
- |
[2] 14, 65 |
143 |
Gammanorm 165 mg/ml |
- |
- |
- |
- |
[1] 65 |
144 |
Gammaplex |
Immune globulin human |
- |
- |
- |
[1] 65 |
145 |
Gammaplex (5%) |
- |
- |
- |
- |
[1] 65 |
146 |
Gammaplex (intravenous immunoglobulin) |
Immune globulin human |
- |
- |
- |
[1] 65 |
147 |
Gammaplex 10 |
- |
- |
- |
- |
[1] 65 |
148 |
Gamunex-c |
Immune globulin human |
- |
- |
- |
[1] 65 |
149 |
Gcsf |
Filgrastim |
D03235 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[3] 36, 65, 284 |
150 |
Gene therapy method for cgd |
- |
- |
- |
- |
[1] 65 |
151 |
Gene transfer |
- |
- |
- |
- |
[1] 65 |
152 |
Gene-transduced autologous cd34+ stem cells |
- |
- |
- |
- |
[1] 65 |
153 |
Genetically modified autologous blood stem cells |
- |
- |
- |
- |
[1] 65 |
154 |
Glycolic acid |
Glycolic acid |
- |
- |
- |
[1] 65 |
155 |
Glycosade |
- |
- |
- |
- |
[3] 65, 256, 257 |
156 |
Gtg003.08 |
- |
- |
- |
- |
[1] 65 |
157 |
Gvhd prophylaxis |
- |
- |
- |
- |
[2] 60, 65 |
158 |
Haemocomplettan p |
- |
- |
- |
- |
[1] 65 |
159 |
Haplo bm with t cell depletion |
- |
- |
- |
- |
[1] 65 |
160 |
Hematopoetic stem cell transplantation |
- |
- |
- |
- |
[5] 19, 65, 120, 160, 326 |
161 |
Hematopoietic stem cell transplant |
- |
- |
- |
- |
[1] 65 |
162 |
Hizentra |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
163 |
Hizentra® |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
164 |
Htlp |
- |
- |
- |
- |
[1] 65 |
165 |
Human fibrinogen |
Fibrinogen human |
- |
- |
- |
[1] 65 |
166 |
Human fibrinogen concentrate |
Fibrinogen human |
- |
- |
- |
[1] 65 |
167 |
Human immunglobulin g (igg) |
- |
- |
- |
- |
[1] 65 |
168 |
Human normal immunoglobulin |
Immune globulin human |
- |
- |
- |
[8] 11, 13, 14, 43, 45, 50, 63, 65 |
169 |
Human normal immunoglobulin (iv) |
Immune globulin human |
- |
- |
- |
[4] 11, 14, 63, 65 |
170 |
Human normal immunoglobulin (ivig) |
Immune globulin human |
- |
- |
- |
[2] 50, 65 |
171 |
Human normal immunoglobulin (subcutaneous - intramuscular immunoglobulin) |
Immune globulin human |
- |
- |
- |
[1] 65 |
172 |
Human normal immunoglobulin for |
Immune globulin human |
- |
- |
- |
[1] 65 |
173 |
Human normal immunoglobulin for intravenous administration |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
174 |
Human normal immunoglobulin for intravenous use |
Immune globulin human |
- |
- |
- |
[2] 63, 65 |
175 |
Human normal immunoglobulin for intravenous use (ivig) |
Immune globulin human |
- |
- |
- |
[1] 65 |
176 |
Human normal immunoglobulin for subcutaneous administration |
Immune globulin human |
- |
- |
- |
[1] 65 |
177 |
Human normal immunoglobulin for subcutaneous administration (igsc) |
Immune globulin human |
- |
- |
- |
[1] 65 |
178 |
Hyaluronidase |
Hyaluronidase |
D04455, D04456, D06604 |
- |
- |
[3] 28, 65, 331 |
179 |
Hyaluronoglucosaminidase |
Hyaluronidase |
D04455, D04456, D06604 |
- |
- |
[1] 65 |
180 |
Hydroxyurea |
Hydroxyurea |
D00341 |
[1] RRM2 |
[6] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
[8] 3, 13, 19, 20, 65, 85, 86, 284 |
181 |
Hyqvia |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
182 |
Hyqvia 100 mg/ml solution for infusion for subcutaneous use |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
183 |
I10e |
- |
- |
- |
- |
[3] 14, 63, 65 |
184 |
Ibuprofen |
Ibuprofen |
D00126, D01122, D04490, D06606 |
[2] PTGS1, PTGS2 |
[21] Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
[6] 13, 46, 65, 113, 271, 299 |
185 |
Ifn-gamma |
- |
- |
- |
- |
[1] 65 |
186 |
Ig vena 50 g/l solution for infusion 100 ml vial + infusion set |
- |
- |
- |
- |
[2] 63, 65 |
187 |
Igg next generation |
- |
- |
- |
- |
[2] 63, 65 |
188 |
Ighy10 |
- |
- |
- |
- |
[1] 65 |
189 |
Igiv, 10% |
- |
- |
- |
- |
[2] 14, 65 |
190 |
Igiv, 10% only |
- |
- |
- |
- |
[1] 65 |
191 |
Igiv-c 10% |
- |
- |
- |
- |
[1] 65 |
192 |
Ignextgen 16% |
- |
- |
- |
- |
[1] 65 |
193 |
Igng |
- |
- |
- |
- |
[1] 65 |
194 |
Igpro10 |
- |
- |
- |
- |
[3] 14, 51, 65 |
195 |
Igpro20 |
- |
- |
- |
- |
[3] 14, 51, 65 |
196 |
Igsc - rhuph20 then igsc or igiv |
- |
- |
- |
- |
[1] 65 |
197 |
Igsc 20% |
- |
- |
- |
- |
[1] 65 |
198 |
Igsc 20% 150 mg/kg |
- |
- |
- |
- |
[1] 65 |
199 |
Igsc 20% daily push versus 2 times per week pump |
- |
- |
- |
- |
[1] 65 |
200 |
Igsc 20% daily push versus every 2 weeks pump |
- |
- |
- |
- |
[1] 65 |
201 |
Igsc 20% daily push versus once a week pump |
- |
- |
- |
- |
[1] 65 |
202 |
Igsc, 16% |
- |
- |
- |
- |
[1] 65 |
203 |
Igsc, 20% |
- |
- |
- |
- |
[1] 65 |
204 |
Immune globulin infusion (human), 10% |
- |
- |
- |
- |
[1] 65 |
205 |
Immune globulin intravenous |
Immune globulin human |
- |
- |
- |
[3] 14, 63, 65 |
206 |
Immune globulin intravenous (human) |
Immune globulin human |
- |
- |
- |
[1] 65 |
207 |
Immune globulin intravenous (human) 5% liquid, ivig-sn™ |
Immune globulin human |
- |
- |
- |
[1] 65 |
208 |
Immune globulin intravenous (human), 10% |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
209 |
Immune globulin intravenous (human), 10% solution |
Immune globulin human |
- |
- |
- |
[1] 65 |
210 |
Immune globulin intravenous (human), 10% tvr (triple virally reduced) solution |
Immune globulin human |
- |
- |
- |
[1] 65 |
211 |
Immune globulin intravenous [human], 10% caprylate/chromatography purified |
Immune globulin human |
- |
- |
- |
[1] 65 |
212 |
Immune globulin subcutaneos, 20% |
Immune globulin human |
- |
- |
- |
[1] 65 |
213 |
Immune globulin subcutaneous |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
214 |
Immune globulin subcutaneous (human) |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
215 |
Immune globulin subcutaneous (human) (scig) |
Immune globulin human |
- |
- |
- |
[1] 65 |
216 |
Immune globulin subcutaneous (human) igpro20 |
Immune globulin human |
- |
- |
- |
[1] 65 |
217 |
Immune globulin subcutaneous (human), 20% |
Immune globulin human |
- |
- |
- |
[1] 65 |
218 |
Immune globulin subcutaneous (human), 20% caprylate/chromatography purified (igsc 20%) |
Immune globulin human |
- |
- |
- |
[1] 65 |
219 |
Immune globulin subcutaneous (human), 20% solution |
Immune globulin human |
- |
- |
- |
[1] 65 |
220 |
Immune globulin subcutaneous (human), 20%, caprylate/chromatography purified |
Immune globulin human |
- |
- |
- |
[1] 65 |
221 |
Immunoglobulin g |
- |
- |
- |
- |
[7] 11, 13, 14, 49, 50, 63, 65 |
222 |
Immunoglobulin g (ig nextgen 16%) |
- |
- |
- |
- |
[1] 65 |
223 |
Immunoglobulin intravenous (human) |
- |
- |
- |
- |
[1] 65 |
224 |
Immunoglobulins intravenous (human) |
- |
- |
- |
- |
[1] 65 |
225 |
Immunological diagnosis tests |
- |
- |
- |
- |
[1] 65 |
226 |
Immunosuppression only conditioning (ioc) |
- |
- |
- |
- |
[1] 65 |
227 |
Immunosuppression only conditioning - closed with amendment l |
- |
- |
- |
- |
[1] 65 |
228 |
Increlex |
Mecasermin |
D03297, D04870 |
[2] GHR, IGF1R |
[33] AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
[3] 65, 78, 96 |
229 |
Infliximab |
Infliximab |
D02598 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[22] 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
230 |
Interferon gamma |
- |
- |
- |
- |
[2] 65, 326 |
231 |
Interferon gamma-1b |
- |
- |
- |
- |
[7] 65, 85, 90, 228, 299, 301, 326 |
232 |
Interferon-gamma |
- |
- |
- |
- |
[1] 65 |
233 |
Interleukin-2 |
Human interleukin-2 |
- |
- |
- |
[6] 2, 35, 49, 55, 65, 97 |
234 |
Intratect |
- |
- |
- |
- |
[3] 13, 35, 65 |
235 |
Intravenous immunoglobulin |
Immune globulin human |
- |
- |
- |
[16] 2, 11, 14, 17, 18, 35, 38, 39, 49, 51, 63, 65, 85, 164, 296, 309 |
236 |
Intravenous infusion of transduced cells |
- |
- |
- |
- |
[1] 65 |
237 |
Itraconazole |
Itraconazole |
D00350 |
- |
- |
[4] 3, 65, 227, 299 |
238 |
Ivig |
Immune globulin human |
- |
- |
- |
[12] 11, 13, 14, 17, 18, 50, 51, 63, 65, 85, 164, 296 |
239 |
Kedrion ivig 10% |
Immune globulin human |
- |
- |
- |
[1] 65 |
240 |
Kineret |
Anakinra |
D02934 |
[2] IL1R1, IL1R2 |
[15] Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
[5] 41, 49, 65, 266, 299 |
241 |
Kiovig |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
242 |
Kiovig 100 mg/ml solution for infusion |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
243 |
L-fucose |
Fucose |
- |
- |
- |
[1] 65 |
244 |
Ladicell |
- |
- |
- |
- |
[1] 65 |
245 |
Lemtrada |
Alemtuzumab |
D02802 |
- |
- |
[2] 13, 65 |
246 |
Lenograstim |
Lenograstim |
D03247 |
[1] CSF3R |
[5] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
[3] 2, 57, 65 |
247 |
Lentiviral g1xcgd gene therapy |
- |
- |
- |
- |
[1] 65 |
248 |
Lentiviral vector transduced cd34+ cells |
- |
- |
- |
- |
[1] 65 |
249 |
Lfb-igsc |
- |
- |
- |
- |
[1] 65 |
250 |
Mabthera |
- |
- |
- |
- |
[15] 11, 13, 35, 46, 50, 51, 53, 61, 63, 64, 65, 83, 162, 222, 271 |
251 |
Mavorixafor |
- |
- |
- |
- |
[1] 65 |
252 |
Mctls |
- |
- |
- |
- |
[1] 65 |
253 |
Medi1123 |
- |
- |
- |
- |
[1] 65 |
254 |
Medi4736 |
- |
- |
- |
- |
[1] 65 |
255 |
Melarsoprol |
Melarsoprol |
D00832 |
- |
- |
[1] 65 |
256 |
Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d |
Eflornithine |
D07883 |
[1] ODC1 |
[3] Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
[1] 65 |
257 |
Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d |
Melarsoprol |
D00832 |
- |
- |
[1] 65 |
258 |
Melphalan |
Melphalan |
D00369 |
- |
- |
[14] 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
259 |
Mesna |
Coenzyme m |
- |
- |
- |
[9] 13, 44, 45, 49, 51, 60, 65, 96, 164 |
260 |
Methotrexate |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
261 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[36] 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
262 |
Methylprednisolone or prednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 65 |
263 |
Mozobil 20mg/ml vial (injectable solution for subcutaneous use) |
Plerixafor |
D08971 |
[1] CXCR4 |
[12] Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
[1] 65 |
264 |
Mozobil 20mg/ml vial (injectable solution, subcutaneous use) |
Plerixafor |
D08971 |
[1] CXCR4 |
[12] Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
[1] 65 |
265 |
Mycophenolate |
Mycophenolic acid |
D05096 |
[2] IMPDH1, IMPDH2 |
[3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
[33] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
266 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
[2] IMPDH1, IMPDH2 |
[3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
[32] 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
267 |
Myeloablative conditioning-closed with amendment l |
- |
- |
- |
- |
[1] 65 |
268 |
Myeloablative preparative regimen |
- |
- |
- |
- |
[3] 62, 65, 284 |
269 |
Myelostim 34 milions ui/ml - powder and solvent for solution for injection/infusion |
- |
- |
- |
- |
[1] 65 |
270 |
Myelostim 34 milions ui/ml, powder and solvent for solution for injection or infusion |
- |
- |
- |
- |
[1] 65 |
271 |
Nanogam 100 mg/ml |
- |
- |
- |
- |
[1] 65 |
272 |
Nanogam® 50 mg/ml |
- |
- |
- |
- |
[1] 65 |
273 |
Neopterin |
Neopterin |
- |
- |
- |
[1] 65 |
274 |
Newgam |
- |
- |
- |
- |
[3] 14, 63, 65 |
275 |
Nifurtimox |
Nifurtimox |
D00833 |
- |
- |
[1] 65 |
276 |
Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d |
Eflornithine |
D07883 |
[1] ODC1 |
[3] Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
[1] 65 |
277 |
Nifurtimox-eflronithine combination treatment (nect) |
Nifurtimox |
D00833 |
- |
- |
[1] 65 |
278 |
Noxafil 40 mg/ml oral solution |
- |
- |
- |
- |
[1] 65 |
279 |
Octagam 10% |
- |
- |
- |
- |
[3] 50, 63, 65 |
280 |
Octagam 5% |
- |
- |
- |
- |
[2] 13, 65 |
281 |
Octagam 50 mg/ml oldatos infúzió |
- |
- |
- |
- |
[1] 65 |
282 |
Octanorm |
- |
- |
- |
- |
[2] 50, 65 |
283 |
Octanorm 16.5% |
- |
- |
- |
- |
[2] 50, 65 |
284 |
Omalizumab |
Omalizumab |
D05251 |
[1] FCER1A |
[4] Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
[6] 53, 65, 98, 162, 226, 299 |
285 |
Omalizumab (xolair) |
Omalizumab |
D05251 |
[1] FCER1A |
[4] Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
[1] 65 |
286 |
Orencia |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[9] 46, 50, 51, 53, 65, 84, 96, 97, 271 |
287 |
Orencia® 125 mg solution for injection in pre-filled syringe |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[1] 65 |
288 |
Otl-101 |
- |
- |
- |
- |
[1] 65 |
289 |
Ovastat |
Treosulfan |
D07253 |
- |
- |
[2] 13, 65 |
290 |
Ovastat 1000 (treosulfan injection) |
Treosulfan |
D07253 |
- |
- |
[1] 65 |
291 |
Ovastat 5000 (treosulfan injection) |
Treosulfan |
D07253 |
- |
- |
[1] 65 |
292 |
Palifermin |
Palifermin |
D05338 |
[1] FGFR2 |
[12] Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells |
[4] 13, 38, 39, 65 |
293 |
Pantoprazole |
Pantoprazole |
D02593, D05353 |
[2] ATP4A, ATP4B |
[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
[2] 13, 65 |
294 |
Pantoprazolo 20 mg gastro-resistant tablets |
- |
- |
- |
- |
[1] 65 |
295 |
Peg-interleukin-2 |
Human interleukin-2 |
- |
- |
- |
[1] 65 |
296 |
Pentamidine |
Pentamidine |
D00834, D08333 |
- |
- |
[1] 65 |
297 |
Phagocyte oxidase subunit transduced cd34 hematopoietic stem cells |
- |
- |
- |
- |
[1] 65 |
298 |
Phosphate |
Phosphate ion |
- |
- |
- |
[29] 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
299 |
Pioglitazone |
Pioglitazone |
D00945, D08378 |
[1] PPARG |
[9] AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer |
[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
300 |
Plerixafor |
Plerixafor |
D08971 |
[1] CXCR4 |
[12] Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
[4] 51, 65, 285, 299 |
301 |
Plerixafor for conditioning before hsct. |
Plerixafor |
D08971 |
[1] CXCR4 |
[12] Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
[1] 65 |
302 |
Pneumo 23 |
- |
- |
- |
- |
[1] 65 |
303 |
Polyclonal igg |
- |
- |
- |
- |
[1] 65 |
304 |
Posaconazole |
Posaconazole |
D02555 |
- |
- |
[3] 60, 65, 299 |
305 |
Posaconazole (psz) |
Posaconazole |
D02555 |
- |
- |
[1] 65 |
306 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[38] 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
307 |
Prednisone |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[43] 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
308 |
Prevenar |
- |
- |
- |
- |
[1] 65 |
309 |
Privigen |
Immune globulin human |
- |
- |
- |
[4] 11, 14, 51, 65 |
310 |
Proleukin® s |
Aldesleukin |
D00748 |
[3] IL2RA, IL2RB, IL2RG |
[14] Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor |
[1] 65 |
311 |
Promacta |
Eltrombopag |
D03978 |
- |
- |
[1] 65 |
312 |
Psrs11.efs.il2rg.pre* retroviral vector |
- |
- |
- |
- |
[1] 65 |
313 |
Psrs11.efs.il2rg.pre* retroviral vector transduce |
- |
- |
- |
- |
[1] 65 |
314 |
Psrs11.efs.il2rg.pre* retroviral vector transduced cells |
- |
- |
- |
- |
[1] 65 |
315 |
Pth 1-34 |
Teriparatide |
D06078 |
[1] PTH1R |
[3] Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
[2] 65, 235 |
316 |
Pyrimethamine |
Pyrimethamine |
D00488 |
- |
- |
[4] 2, 4, 19, 65 |
317 |
Rabbit |
Rabbit |
- |
- |
- |
[7] 13, 49, 51, 60, 65, 96, 285 |
318 |
Rabbit anti-thymocyte globulin |
Rabbit |
- |
- |
- |
[2] 49, 65 |
319 |
Ranitidine |
Ranitidine |
D00422, D00673 |
[1] HRH2 |
[3] Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
[2] 13, 65 |
320 |
Recombinant human hyaluronidase |
Hyaluronidase |
D04455, D04456, D06604 |
- |
- |
[2] 28, 65 |
321 |
Recombinant human hyaluronidase (rhuph20) |
Hyaluronidase |
D04455, D04456, D06604 |
- |
- |
[1] 65 |
322 |
Recombinant human hyaluronidase (rhuph20)+ immune globulin intravenous (igiv) |
Hyaluronidase |
D04455, D04456, D06604 |
- |
- |
[1] 65 |
323 |
Recombinant human hyaluronidase + immune globulin intravenous |
Hyaluronidase |
D04455, D04456, D06604 |
- |
- |
[1] 65 |
324 |
Reduced intensity conditioning |
- |
- |
- |
- |
[2] 19, 65 |
325 |
Reduced intensity conditioning (ric) |
- |
- |
- |
- |
[1] 65 |
326 |
Reduced intensity preparative regimen |
- |
- |
- |
- |
[3] 62, 65, 284 |
327 |
Reduced toxicity ablative regimen |
- |
- |
- |
- |
[3] 62, 65, 284 |
328 |
Retroviral sf71-gp91phox transduced cd34+ cells |
- |
- |
- |
- |
[1] 65 |
329 |
Retrovirus-mediated gene transfer |
- |
- |
- |
- |
[1] 65 |
330 |
Rhucd40l |
- |
- |
- |
- |
[1] 65 |
331 |
Ri-002 |
- |
- |
- |
- |
[1] 65 |
332 |
Rimiducid |
- |
- |
- |
- |
[5] 19, 65, 284, 285, 326 |
333 |
Rituximab |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
334 |
Rituximab (rtx) and azathioprine (aza) |
Azathioprine |
D00238, D03033 |
- |
- |
[1] 65 |
335 |
Rivogenlecleucel |
- |
- |
- |
- |
[4] 19, 65, 284, 285 |
336 |
Roxadustat |
Roxadustat |
D10593 |
[3] EGLN1, EGLN2, EGLN3 |
[3] HIF-1 signaling pathway, Pathways in cancer, Renal cell carcinoma |
[1] 65 |
337 |
Rp-l201 |
- |
- |
- |
- |
[1] 65 |
338 |
Scid screening |
- |
- |
- |
- |
[1] 65 |
339 |
Scyx 7158 |
- |
- |
- |
- |
[1] 65 |
340 |
Scyx-7158 |
- |
- |
- |
- |
[1] 65 |
341 |
Sirolimus |
Sirolimus |
D00753 |
[1] MTOR |
[43] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
[30] 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
342 |
Somatic gene-therapy by x-cgd |
- |
- |
- |
- |
[1] 65 |
343 |
Sta-5326 |
- |
- |
- |
- |
[2] 65, 96 |
344 |
Stelara (ustekinumab) |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[1] 65 |
345 |
Stem cell transplant |
- |
- |
- |
- |
[2] 60, 65 |
346 |
Stem cell transplantation |
- |
- |
- |
- |
[9] 13, 19, 20, 46, 65, 90, 164, 234, 326 |
347 |
Strimvelis |
- |
- |
- |
- |
[1] 65 |
348 |
Subcuvia |
- |
- |
- |
- |
[3] 14, 49, 65 |
349 |
Subgam |
- |
- |
- |
- |
[1] 65 |
350 |
Sulfadoxine |
Sulfadoxine |
D00580 |
- |
- |
[1] 65 |
351 |
Suspension of autologous cd34+cells transduced with the g1xcgd viral vector |
- |
- |
- |
- |
[1] 65 |
352 |
T-cell depleted & cd34+select/w/stemcell enriched product |
- |
- |
- |
- |
[1] 65 |
353 |
Tabelecleucel |
- |
- |
- |
- |
[1] 65 |
354 |
Tablets fexinidazole |
Fexinidazole |
D11252 |
- |
- |
[1] 65 |
355 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
[5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
[30] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
[29] 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
356 |
Tadekinig alfa |
Tadekinig alfa |
- |
- |
- |
[1] 65 |
357 |
Tbx-1400 |
- |
- |
- |
- |
[1] 65 |
358 |
Tcr alfa beta t cell depletion |
- |
- |
- |
- |
[1] 65 |
359 |
Thalidomide |
Thalidomide |
D00754 |
[1] TNF |
[61] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
[18] 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
360 |
Therapeutic allogeneic lymphocytes |
- |
- |
- |
- |
[2] 60, 65 |
361 |
Thiotepa |
Thiotepa |
D00583 |
- |
- |
[11] 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 |
362 |
Thiotepa--escalated dose |
Thiotepa |
D00583 |
- |
- |
[4] 19, 20, 65, 284 |
363 |
Thiotepa--single daily dose |
Thiotepa |
D00583 |
- |
- |
[4] 19, 20, 65, 284 |
364 |
Thymoglobuline |
- |
- |
- |
- |
[4] 13, 36, 51, 65 |
365 |
Thymus tissue for transplantation |
- |
- |
- |
- |
[1] 65 |
366 |
Thymus/parathyroid transplantation |
- |
- |
- |
- |
[2] 65, 235 |
367 |
Traditional treatment of cgd and tb |
- |
- |
- |
- |
[1] 65 |
368 |
Transduced lymphocytes |
- |
- |
- |
- |
[1] 65 |
369 |
Transplant conditioning with mobilization and alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
[1] 65 |
370 |
Transplant conditioning with mobilization only |
- |
- |
- |
- |
[1] 65 |
371 |
Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan |
Alemtuzumab, Fludarabine |
D01907, D02802, D07966 |
[1] RRM1 |
[5] Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
[2] 65, 164 |
372 |
Tremelimumab |
Tremelimumab |
D06657 |
[1] CTLA4 |
[4] Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Rheumatoid arthritis, T cell receptor signaling pathway |
[1] 65 |
373 |
Treosulfan |
Treosulfan |
D07253 |
- |
- |
[3] 13, 19, 65 |
374 |
Tyf-il-2rg gene-modified autologous stem cells |
- |
- |
- |
- |
[1] 65 |
375 |
Unrelated bm with t cell depletion |
- |
- |
- |
- |
[1] 65 |
376 |
Unrelated cord blood |
- |
- |
- |
- |
[1] 65 |
377 |
Ustekinumab |
Ustekinumab |
D09214 |
[3] IL12A, IL12B, IL23A |
[25] African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
[15] 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 |
378 |
Valacyclovir |
Valaciclovir |
D00398, D08664, D10518 |
- |
- |
[1] 65 |
379 |
Valproic acid |
Valproic acid |
D00399 |
[7] ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 |
[17] Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
[10] 3, 5, 26, 34, 65, 89, 90, 222, 256, 331 |
380 |
Verorab® (pvrv |
- |
- |
- |
- |
[1] 65 |
381 |
Vigantol |
- |
- |
- |
- |
[2] 13, 65 |
382 |
Vitamin d3 |
Cholecalciferol |
D00188 |
[1] VDR |
[4] Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
[11] 6, 13, 20, 46, 49, 53, 60, 65, 96, 97, 299 |
383 |
Vivaglobin |
Immune globulin human |
- |
- |
- |
[2] 14, 65 |
384 |
Vm106 |
- |
- |
- |
- |
[1] 65 |
385 |
Water |
Water |
D00001 |
- |
- |
[18] 2, 5, 6, 13, 17, 19, 35, 46, 53, 57, 63, 65, 67, 84, 97, 226, 278, 299 |
386 |
X4p-001 |
- |
- |
- |
- |
[1] 65 |
387 |
Xifaxan |
Rifaximin |
D02554 |
- |
- |
[2] 65, 94 |
388 |
Zoledronate |
Zoledronic acid |
D01968, D06378, D06379, D08689 |
[1] FDPS |
[4] Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
[2] 46, 65 |